Novartis India Ltd Approves Unaudited Financial Results for Quarter Ended June 30, 2026
Novartis India Limited has approved its unaudited financial results and a Limited Review Report for the quarter ending June 30, 2026. The Board of Directors reviewed the financials, which were subjected to limited review by the company's Statutory Auditors and recommended by the Audit Committee.The Statement of Unaudited Financial Results details operational performance across various periods, including the three months ended June 30, 2026. Key financial metrics include:
| Metric | Three Months Ended June 30, 2026 | Three Months Ended March 31, 2026 |
|---|---|---|
| Revenue from Operations & Other Income | 1,83.4 (in million) | 1,000.4 (in million) |
| Changes in Stock-in Trade | 760.5 (in million) | 683.4 (in million) |
| Total Expenses | 203.8 (in million) | 43.5 (in million) |
| Profit Before Tax | 322.1 (in million) | 48.9 (in million) |
| Earnings Per Share (Basic & Diluted) | Not disclosed | 37.74 (per share) |
The company operates within a single segment, the Pharmaceutical Business, and generates revenues from its operations in India. The results highlight the dependency on one customer; for the quarter ended June 30, 2026, revenue from this specific customer was R 532.9 million, which constitutes more than 10% of the total revenue from the sale of traded goods.
Material Transaction in Shareholding
Separately, it was reported that Novartis AG entered into an Agreement for the sale and purchase of Sale Shares in Novartis India Limited on February 19, 2026. The transaction involves WaveRise Investments Limited (Acquirer 1), ChrysCapital Fund X (Acquirer 2), and Two Infinity Partners (Acquirer 3) (collectively referred to as the "Acquirers").
Under the agreement, Novartis AG agreed to sell 174,50,680 fully paid-up equity shares of the Company, representing 70.68% of the equity share capital. Following this acquisition, the Acquirers are expected to acquire control over the Company and will be classified as the promoter.
Furthermore, an open offer was conducted by the Acquirer in accordance with SEBI SAST Regulations, which was closed on June 24, 2026.
Labour Code Impact Assessment
The company also detailed its impact assessment following the notification of four Labour Codes by the Government of India on November 21, 2025. The company recognized an increase in the provision for employee benefits for the year ended March 31, 2026, amounting to Z 7.9 million. This increase includes 4.4 million for Gratuity and 3.5 million for leave benefits, which were accounted for as employee benefit expense in the financial results, consistent with Ind AS 19 - Employee Benefits.
NOVARTIND Stock Price Movement
Shares of Novartis India Limited are shedding value as of 1:16 PM, trading at ₹1687.2 after dipping by 0.74% in live market action. The stock remains near its peak performance level, having touched a spectacular 52-week high of ₹1780 amidst significant activity involving 121,072 shares traded.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.